Resources from the same session
Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Presenter: Alexander Eggermont
Session: Presidential Symposium 1
Resources:
Abstract
Presentation
Invited discussant LBA3
Presenter: Sandro Pignata
Session: Presidential Symposium 1
Resources:
Presentation
Invited discussant LBA2
Presenter: Olivier Michielin
Session: Presidential Symposium 1
Resources:
Presentation
First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Presenter: Gabriel Hortobagyi
Session: Presidential Symposium 1
Resources:
Abstract
Presentation
A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Presenter: Mansoor Raza Mirza
Session: Presidential Symposium 1
Resources:
Abstract
Presentation